Phase II Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer
The purpose of this study is to determine whether DCVAC/PCa added onto Standard of Care therapy can improve survival times for patients with Metastatic Castration Resistant Prostate Cancer
Prostate Cancer|Prostate Cancer Metastatic
BIOLOGICAL: Dendritic Cells DCVAC/PCa|DRUG: Docetaxel
Survival rate, 135 weeks
Radiographic Progression Free Survival, 135 weeks|Duration to Prostate Specific Antigen (PSA) Progression, 135 weeks|Changes in Quality of Life (QOL) assessed by European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30, 0, 10, 22, 37, 53, 65 weeks|Changes in Pain assessed by EORTC QLQ-C30, 0, 10, 22, 37, 53, 65 weeks|Incidence of Adverse Events, 135 weeks
The purpose of this study is to determine whether DCVAC/PCa added onto Standard of Care therapy can improve survival times for patients with Metastatic Castration Resistant Prostate Cancer